Biogen Inc. – LSE:0R1B.L
Biogen stock price today
Biogen stock price monthly change
Biogen stock price quarterly change
Biogen stock price yearly change
Biogen key metrics
Market Cap | 21.28B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 8.05 |
Revenue | 9.57B |
EBITDA | 2.39B |
Income | 1.16B |
Revenue Q/Q | -10.66% |
Revenue Y/Y | -5.26% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 25.03% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBiogen stock price history
Biogen stock forecast
Biogen financial statements
| Jun 2023 | 2.45B | 591.6M | 24.09% |
|---|---|---|---|
| Sep 2023 | 2.53B | -68.1M | -2.69% |
| Dec 2023 | 2.38B | 249.7M | 10.46% |
| Mar 2024 | 2.20B | 393.4M | 17.88% |
| Sep 2025 | 2.35B | 580.63M | 24.67% |
|---|---|---|---|
| Oct 2025 | 2.39B | 581.53M | 24.31% |
| Dec 2025 | 2.41B | 549.34M | 22.71% |
| Mar 2026 | 2.30B | 576.65M | 24.98% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 25156800000 | 10.69B | 42.52% |
|---|---|---|---|
| Sep 2023 | 28193200000 | 13.71B | 48.64% |
| Dec 2023 | 26844800000 | 12.04B | 44.87% |
| Mar 2024 | 26567600000 | 11.35B | 42.74% |
| Jun 2023 | 487M | -753.5M | -9.8M |
|---|---|---|---|
| Sep 2023 | 592.4M | -1.74B | 848.6M |
| Dec 2023 | 12.5M | -652.3M | -646.1M |
| Mar 2024 | 553.2M | -66M | -439.6M |
Biogen alternative data
| Aug 2023 | 7,400 |
|---|---|
| Sep 2023 | 7,400 |
| Oct 2023 | 7,400 |
| Nov 2023 | 7,400 |
| Dec 2023 | 7,400 |
| Jan 2024 | 7,400 |
| Feb 2024 | 7,400 |
| Mar 2024 | 7,400 |
| Apr 2024 | 7,400 |
| May 2024 | 7,400 |
| Jun 2024 | 7,400 |
| Jul 2024 | 7,570 |
Biogen other data
| Patent |
|---|
Application Filling date: 17 May 2021 Issue date: 31 Mar 2022 |
Application Filling date: 15 Oct 2021 Issue date: 3 Feb 2022 |
Grant Filling date: 5 Oct 2018 Issue date: 7 Dec 2021 |
Grant Filling date: 10 Oct 2018 Issue date: 19 Oct 2021 |
Application Filling date: 5 May 2020 Issue date: 28 Jan 2021 |
Application Filling date: 10 Oct 2018 Issue date: 15 Oct 2020 |
Application Filling date: 5 Oct 2018 Issue date: 27 Aug 2020 |
Application Filling date: 28 Sep 2018 Issue date: 13 Aug 2020 |
Grant Utility: Method for treating joint damage Filling date: 30 Jul 2019 Issue date: 19 May 2020 |
Application Filling date: 30 Jul 2019 Issue date: 19 Dec 2019 |
-
What's the price of Biogen stock today?
One share of Biogen stock can currently be purchased for approximately $246.65.
-
When is Biogen's next earnings date?
Unfortunately, Biogen's (0R1B.L) next earnings date is currently unknown.
-
Does Biogen pay dividends?
No, Biogen does not pay dividends.
-
How much money does Biogen make?
Biogen has a market capitalization of 21.28B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 3.32% to 9.84B US dollars.
-
What is Biogen's stock symbol?
Biogen Inc. is traded on the LSE under the ticker symbol "0R1B.L".
-
What is Biogen's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Biogen?
Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Biogen have?
As Jul 2024, Biogen employs 7,570 workers, which is 2% more then previous month and 2% more then previous quarter.
-
When Biogen went public?
Biogen Inc. is publicly traded company for more then 33 years since IPO on 17 Sep 1991.
-
What is Biogen's official website?
The official website for Biogen is biogen.com.
-
Where are Biogen's headquarters?
Biogen is headquartered at 225 Binney St, Cambridge, MASSACHUSETTS.
-
How can i contact Biogen?
Biogen's mailing address is 225 Binney St, Cambridge, MASSACHUSETTS and company can be reached via phone at +1 781 464 2000.
Biogen company profile:
Biogen Inc.
biogen.comLSE
7,570
Medical - Pharmaceuticals
Healthcare
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,800 full-time employees. The firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The firm's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Cambridge, MASSACHUSETTS
:
ISIN: US09062X1037
:
